Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to test the idea that the immediate-release (IR) form of
tapentadol (CG5503) can be directly converted into an approximately equivalent total daily
dose (TDD) of the extended-release (ER) form, and vice-versa, with equivalent safety and
efficacy.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.